Hal Barron

Type: Person
Name: Hal Barron
First reported Apr 22 2014 - Updated Apr 22 2014 - 1 reports

Google adds UCSF geneticist to Calico's roster

Calico's Cynthia Kenyon--Courtesy of UCSFIn the months since details of Google's ($GOOG) Calico last leaked into the public domain, the creation of a new J. Craig Venter company has further increased interest in anti-aging. And while Calico has been out ... [Published Fierce Biotech IT - Apr 22 2014]
First reported Apr 20 2014 - Updated Apr 21 2014 - 1 reports

Google Scoops Up Another High-Profile Scientist For Anti-Death Project

Google’s secretive Project Calico is aimed at defeating death itself — or at least staving it off far longer than ever before.To that end, the company has been recruiting some of the top names in anti-aging and genetics research. The latest is Cynthia ... [Published Business Insider - Apr 20 2014]
First reported Mar 19 2014 - Updated Mar 19 2014 - 2 reports

FDA Advisory Committee Recommends Accelerated Approval of Genentech’s Perjeta for Neoadjuvant Use in HER2-Positive Early Stage Breast Cancer

/ Media / Press ReleasesThursday, Sep 12, 2013The FDA Will Make a Final Decision by October 31 The Perjeta Regimen is the First Potential Treatment to be Reviewed by the FDA for Neoadjuvant Use in Breast CancerSilver Spring, Md. -- September 12, 2013 ... [Published Genentech - Mar 19 2014]
First reported Mar 19 2014 - Updated Mar 19 2014 - 1 reports

FDA Files Genentech’s Supplemental Biologics License Application of Xolair® (omalizumab) for Chronic Idiopathic Urticaria (CIU)

/ Media / Press ReleasesThursday, Oct 10, 2013CIU is a skin condition characterized by red, swollen, itchy hives
 Currently, H1-antihistamines are the only approved therapy for patients suffering from CIU, also known as chronic spontaneous urticaria (CSU)
 ... [Published Genentech - Mar 19 2014]
First reported Mar 19 2014 - Updated Mar 19 2014 - 1 reports

BV 4 Portfolio Company Chiasma and Roche Announce Collaboration to Develop and Commercialize Chiasma’s Octreolin® for Acromegaly and Neuroendocrine Tumors

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Chiasma (pronounced key-azma) Inc., a privately held biopharma company, announced today that they have entered into an agreement to develop and commercialize Chiasma’s proprietary product Octreolin, initially for ... [Published MPM Capital Partners - Mar 19 2014]
First reported Dec 20 2013 - Updated Dec 20 2013 - 1 reports

Larry Ellison’s foundation cuts funding for anti-aging research

Flickr Oracle founder Larry Ellison Oracle founder Larry Ellison’s foundation  will soon stop funding anti-aging and medical research. The foundation was one of the largest funding sources for promising research into anti-aging technologies.  According ... [Published Venturebeat - Dec 20 2013]
First reported Dec 07 2013 - Updated Dec 07 2013 - 1 reports

This anti-aging brain trust is the most interesting startup in Silicon Valley

Flickr/ light-seeker In September,  Google chief executive Larry Page announced his latest “moonshot,” a mysterious new venture to extend the human life span. We don’t know much yet about the initiative, dubbed Calico, but Page revealed in a blog ... [Published Venturebeat - Dec 07 2013]
First reported Nov 21 2013 - Updated Nov 21 2013 - 1 reports

Calico enlists a genetics A-Team for its mysterious anti-aging venture

Gene.com Calico's chief executive Art Levinson Dec. 4 - 5, 2013 Redwood City, CA Tickets on Sale Now In September, Google announced a mysterious new venture to combat death itself. Google’s top executives didn’t say much about the anti-aging ... [Published Venturebeat - Nov 21 2013]
First reported Nov 14 2013 - Updated Nov 14 2013 - 1 reports

Genentech CMO Hal Barron Joins Building Biotechs to Last Dec. 9

Home » Blogs » Genentech CMO Hal Barron Joins ‘Building Biotechs to Last’ Dec. 9Hal Barron, when he was a young physician, joined Genentech as a clinical scientist back in 1996. It was the year of Genentech’s 20th anniversary. It sounds hard to believe ... [Published BioPortfolio - Nov 14 2013]
First reported Nov 09 2013 - Updated Nov 09 2013 - 1 reports

Roche announces positive data from phase III CLL11 study

Roche, the world’s largest biotech company, has released new, positive data from the second stage of the CLL11 study. This phase III study, conducted in cooperation with the German CLL Study Group, compared Gazyva (obinutuzumab), also known as GA101, ... [Published PharmaBiz - Nov 09 2013]
First reported Nov 04 2013 - Updated Nov 05 2013 - 1 reports

US FDA approves Roche's Gazyva combination vaccine to treat CLL patients

The US Food and Drug Administration (FDA) has approved Roche's new drug Gazyva (obinutuzumab) in combination with chlorambucil chemotherapy for treatment of patients with chronic lymphocytic leukemia (CLL) who have not previously been treated.Gazyva is ... [Published Pharmaceutical Business Review - Nov 04 2013]

Quotes

...our application for Xolair for chronic idiopathic urticaria," said Hal Barron, M D , chief medical officer and head, Global Product Development. "we hope we can soon bring our medicine to people with this chronic form of hives."
Roche chief medical officer and head of Global Product Development Hal Barron said, "gazyva is an important new medicine for people with newly diagnosed chronic lymphocytic leukemia as based on clinical data, it more than doubled the time people lived without their disease worsening compared to chlorambucil alone." The CLL11 trial demonstrated that people who were given Gazyva in combination with chlorambucil chemotherapy had reduced risk of disease progression...
...prevented by earlier treatment with a medicine such as Actemra," said Hal Barron, MD, chief medical officer and head, Global Product Development. "we're pleased that these patients will now have the option of actemra as a subcutaneous injection or an iv infusion."
...show the promise that GA101 could hold for people with CLL,” said Hal Barron, Roche’s chief medical officer and head, Global Product Development. "it is important to explore the potential of this medicine in other types of blood cancer, and our broad development program includes studies in aggressive and indolent lymphoma that compare ga101with mabthera/rituxan."

More Content

All (18) | News (14) | Reports (0) | Blogs (4) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Google adds UCSF geneticist to Calico's roster [Published Fierce Biotech IT - Apr 22 2014]
Google Scoops Up Another High-Profile Scientist... [Published Business Insider - Apr 20 2014]
Google scoops up another high-profile scientist... [Published Venturebeat - Apr 20 2014]
Geneticist Cynthia Kenyon heading to Google [Published San Francisco Chronicle - Apr 20 2014]
FDA Files Genentech’s Supplemental Biologics Li... [Published Genentech - Mar 19 2014]
FDA Advisory Committee Recommends Accelerated A... [Published Genentech - Mar 19 2014]
Genentech’s Kadcyla Helped People With Advanced... [Published Genentech - Mar 19 2014]
BV 4 Portfolio Company Chiasma and Roche Announ... [Published MPM Capital Partners - Mar 19 2014]
Larry Ellison’s foundation cuts funding for ant... [Published Venturebeat - Dec 20 2013]
This anti-aging brain trust is the most interes... [Published Venturebeat - Dec 07 2013]
Calico enlists a genetics A-Team for its myster... [Published Venturebeat - Nov 21 2013]
Genentech CMO Hal Barron Joins Building Biotech... [Published BioPortfolio - Nov 14 2013]
Roche announces positive data from phase III CL... [Published PharmaBiz - Nov 09 2013]
US FDA approves Roche's Gazyva combination vacc... [Published Pharmaceutical Business Review - Nov 04 2013]
US FDA approves Roche's subcutaneous formulatio... [Published PharmaBiz - Oct 24 2013]
FDA files Genentech's supplemental biologics li... [Published Pharmaceutical Business Review - Oct 11 2013]
Roche announces positive results from phase III... [Published PharmaBiz - Jul 25 2013]
Do clinical trials work? [Published Bend Bulletin - Jul 21 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Google scoops up another high-profile scientist... [Published Venturebeat - Apr 20 2014]
Above: New Calico recruit Dr. Cynthia Kenyon. Image Credit: UCSF Kenyon Lab Google’s secretive Project Calico is aimed at defeating death itself — or at least staving it off far longer than ever before. To that end, the company has been recruiting ...
Larry Ellison’s foundation cuts funding for ant... [Published Venturebeat - Dec 20 2013]
Flickr Oracle founder Larry Ellison Oracle founder Larry Ellison’s foundation  will soon stop funding anti-aging and medical research. The foundation was one of the largest funding sources for promising research into anti-aging technologies.  According ...
This anti-aging brain trust is the most interes... [Published Venturebeat - Dec 07 2013]
Flickr/ light-seeker In September,  Google chief executive Larry Page announced his latest “moonshot,” a mysterious new venture to extend the human life span. We don’t know much yet about the initiative, dubbed Calico, but Page revealed in a blog ...
Calico enlists a genetics A-Team for its myster... [Published Venturebeat - Nov 21 2013]
Gene.com Calico's chief executive Art Levinson Dec. 4 - 5, 2013 Redwood City, CA Tickets on Sale Now In September, Google announced a mysterious new venture to combat death itself. Google’s top executives didn’t say much about the anti-aging ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.